Bioretec Ltd Unveils Rights Issue Exemption Document for Shareholders
On March 27, 2026, Bioretec Ltd, a pioneering Finnish medical device company, announced the initiation of a rights issue aimed at its existing shareholders. This move allows current investors to subscribe to up to 1,477,828,416 new shares at a minimal price of EUR 0.01 per share, reinforcing the company's commitment to fostering shareholder participation and financial health.
The exemption document concerning this rights issue has been prepared in adherence to the European Parliament and Council Regulation (EU) 2017/1129, specifically addressing Article 1(4)(db) of the Prospectus Regulation. This document is a vital piece of information for shareholders, providing essential insights into the offering and will be made available on Bioretec’s official website from April 2, 2026.
Starting April 7, 2026, the subscription period will commence, allowing shareholders until April 21, 2026, to affirm their interest in acquiring new shares. This window provides ample time for investors to evaluate their options, as subscription rights will also be tradable on the Nasdaq First North Growth Market between April 7 and April 15, 2026.
Bioretec's proactive approach includes the collaboration of DNB Carnegie Investment Bank AB, acting as the sole global coordinator for this rights issue. Legal representation is provided by Krogerus Attorneys Ltd for the company and Borenius Attorneys Ltd for the global coordinator. These partnerships are integral in ensuring a smooth and legally compliant rights offering process.
Background on Bioretec reveals a company deeply invested in the advancement of orthopedic care. It specializes in innovative biodegradable implant technologies, designed to enhance bone growth and improve recovery outcomes for patients following orthopedic surgery. Bioretec's flagship products, the RemeOs™ line, leverage advanced materials like a magnesium alloy and hybrid composites. This next-generation solution is engineered for superior absorption and replacement by natural bone, eliminating the necessity of removal surgery while promoting fracture healing. RemeOs received market authorization in the U.S. by March 2023 and was granted CE mark approval in Europe in January 2025.
Additionally, the Activa product line showcases fully bioabsorbable orthopedic implants tailored for various applications in both adult and pediatric patients. This duo exemplifies Bioretec's dedication to reshaping orthopedic treatments, prioritizing healing through absorption over traditional methods.
In drawing shareholders’ attention to the rights issue, Bioretec stands at the intersection of innovation and investor engagement, further establishing itself as a leader in the medical device sector. The impending rights issue not only aims to empower shareholders but also solidifies the company's stronghold in advancing patient-friendly solutions in orthopedic surgery.
For further information, stakeholders can visit Bioretec’s official site, where the detailed exemption document and other relevant materials will be hosted, ensuring transparency and accessibility as they navigate the subscription process.
As Bioretec continues its journey toward redefining orthopedic care, this rights issue symbolizes an opportunity for existing shareholders to enhance their investment while supporting a company at the forefront of medical advancement.
The exemption document concerning this rights issue has been prepared in adherence to the European Parliament and Council Regulation (EU) 2017/1129, specifically addressing Article 1(4)(db) of the Prospectus Regulation. This document is a vital piece of information for shareholders, providing essential insights into the offering and will be made available on Bioretec’s official website from April 2, 2026.
Starting April 7, 2026, the subscription period will commence, allowing shareholders until April 21, 2026, to affirm their interest in acquiring new shares. This window provides ample time for investors to evaluate their options, as subscription rights will also be tradable on the Nasdaq First North Growth Market between April 7 and April 15, 2026.
Bioretec's proactive approach includes the collaboration of DNB Carnegie Investment Bank AB, acting as the sole global coordinator for this rights issue. Legal representation is provided by Krogerus Attorneys Ltd for the company and Borenius Attorneys Ltd for the global coordinator. These partnerships are integral in ensuring a smooth and legally compliant rights offering process.
Background on Bioretec reveals a company deeply invested in the advancement of orthopedic care. It specializes in innovative biodegradable implant technologies, designed to enhance bone growth and improve recovery outcomes for patients following orthopedic surgery. Bioretec's flagship products, the RemeOs™ line, leverage advanced materials like a magnesium alloy and hybrid composites. This next-generation solution is engineered for superior absorption and replacement by natural bone, eliminating the necessity of removal surgery while promoting fracture healing. RemeOs received market authorization in the U.S. by March 2023 and was granted CE mark approval in Europe in January 2025.
Additionally, the Activa product line showcases fully bioabsorbable orthopedic implants tailored for various applications in both adult and pediatric patients. This duo exemplifies Bioretec's dedication to reshaping orthopedic treatments, prioritizing healing through absorption over traditional methods.
In drawing shareholders’ attention to the rights issue, Bioretec stands at the intersection of innovation and investor engagement, further establishing itself as a leader in the medical device sector. The impending rights issue not only aims to empower shareholders but also solidifies the company's stronghold in advancing patient-friendly solutions in orthopedic surgery.
For further information, stakeholders can visit Bioretec’s official site, where the detailed exemption document and other relevant materials will be hosted, ensuring transparency and accessibility as they navigate the subscription process.
As Bioretec continues its journey toward redefining orthopedic care, this rights issue symbolizes an opportunity for existing shareholders to enhance their investment while supporting a company at the forefront of medical advancement.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.